MétaCan
Menu
Back to cohort
Record W2275754697

High-throughput screening for compounds toxic to human leukemic cells derived from lineage-depleted cord blood cells

2007· article· en· W2275754697 on OpenAlexaff
Sean McDermott, John E. Dick

Bibliographic record

VenueMolecular Cancer Therapeutics · 2007
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer therapeutics and mechanisms
Canadian institutionsUniversity Health Network
Fundersnot available
KeywordsLeukemiaHaematopoiesisStem cellCancer researchCancer cellBiologyCancer stem cellProgenitor cellPopulationCord bloodCancerCell cultureImmunologyCell biologyMedicineGenetics
DOInot available

Abstract

fetched live from OpenAlex

A98 Over the past 10 years, research has conclusively shown the existence of a rare population of cancer cells, termed cancer stem cells, in leukemia, brain, colon, and breast cancers. These cells are biologically distinct from bulk cells and are the only cells able to initiate and sustain the disease. Recent experiments indicate that standard chemotherapy for leukemia is less effective against leukemia stem cells (LSC) than bulk leukemia cells and typically does not spare normal hematopoietic stem cells (HSC) and progenitor cells leading to myelosuppression, indicating that a new paradigm is needed to develop cancer therapeutics that effectively eradicate the disease by targeting the LSC. Here, we sought to identify compounds that selectively target LSC but not normal HSC. The novelty of this proposal is to use populations enriched for LSC and HSC, instead of cancer cell lines, in high-throughput screening of small chemical libraries. Recently, we generated human leukemia cell lines by direct transformation of normal human primitive hematopoietic cells (Lin(-) CB cells) with leukemogenic fusion oncogenes, TLS-ERG and MLL-ENL1. These cells exhibit features of LSC, such as hierarchical organization, engraftment of NOD/SCID mice, and a differentiation block, and have been stably maintained in culture for over a year. As a proof of principle, we screened two of the leukemia cell lines, TEX and M9-ENL1, using a simple cell-growth inhibition assay. We used three libraries of small chemicals comprising over 4000 unique known bioactive, off-patent, and natural compounds. 200 compounds (5%) were scored as positive against either TEX or M9-ENL1 cells. For further IC50 studies, we concentrated on the top 80 compounds that inhibited cell growth to 25% of controls. Numerous anti-cancer therapeutics (paclitaxel, etoposide, and vincristine), general cytotoxic agents (brefeldin), and the digitalis family of ion pump inhibitors (digoxin, ouabain) were identified. At this point, we removed 25 redundant compounds and screened 55 compounds on Lin(-) CB cells to identify compounds more specific for leukemia cells than normal cells. Half of the compounds were toxic to Lin(-) CB cells; Lin(-) CB cells were more sensitive than the leukemias for a third of the compounds; and 10 compounds had more activity on both leukemias than Lin(-) CB cells. Currently, we are testing these top 10 compounds using in vitro progenitor assays and will validate the compounds using the NOD/SCID xenotransplantation model. These approaches will rapidly identify potential agents for the development of therapies directly targeting LSC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.299
Teacher spread0.269 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicCancer therapeutics and mechanismsFrench-language works237,207